JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ara Ketchedjian
Richard Hopkins
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ketchedjian, A.
Right arrow Articles by Hopkins, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ketchedjian, A.
Right arrow Articles by Hopkins, R.
Related Collections
Right arrow Valve disease

J Thorac Cardiovasc Surg 2005;129:159-166
© 2005 The American Association for Thoracic Surgery

Evolving Technology

Ovine panel reactive antibody assay of HLA responsivity to allograft bioengineered vascular scaffolds

Ara Ketchedjian, MDa, Paula Kreuger, BSa, Howard Lukoff, BSa, Elliot Robinson, BSa, Alyce Linthurst-Jones, MSb, Katrina Crouch, BSb, Lloyd Wolfinbarger, PhDb, Richard Hopkins, MDa,*

a Division of Cardiothoracic Surgery and the Collis Surgical Research Laboratory, Brown University, Providence, RI
b Lifenet, Virginia Beach, Va

Read at the Georgia Institute of Technology Workshop, Hilton Head, SC, March 10, 2004.

Received for publication March 15, 2004; revisions received June 15, 2004; accepted for publication June 22, 2004.

* Address for reprints: Richard A. Hopkins, MD, Department of Cardiothoracic Surgery, Rhode Island Hospital, Brown University, 500 MOC, 2 Dudley St, Providence, RI 02905 (E-mail: rahopkins{at}lifespan.org).

BACKGROUND: Increasing evidence implicates immune response as a contributing factor in the failure of allograft valve transplants. Increases in panel reactive antibodies have been identified in human subjects. To correlate these responses with novel preimplantation processing methods to reduce cellularity, both a relevant panel reactive antibody assay and a chronic implantation animal model are necessary. We modified a human flow cytometric panel reactive antibody assay for ovine model use to detect antibody responses to residual antigen-loading decellularized scaffolds engineered from pulmonary artery tissue.

METHODS: A clinical panel reactive antibody assay was modified with anti-sheep antibodies. Dimethyl sulfoxide cryopreserved (n = 4) and decellularized scaffolds (n = 8) fashioned as patches from pulmonary arteries were implanted for study. Fresh (nonprocessed) tissue implants were used as positive controls (n = 2), and sham-treated animals were used as negative controls (n = 2). Baseline, 10-week, and 20-week blood samples were assayed for panel reactive antibody levels. Immunohistochemistry with anti–major histocompatibility complex antibodies were performed on preimplantation scaffolds.

RESULTS: Chronic implants of fresh tissue stimulated strong panel reactive antibody responses. Classically cryopreserved tissues provoked modest panel reactive antibody responses to major histocompatibility complex I antigen and no response to major histocompatibility complex II antigen. Decellularized tissue scaffolds provoked minimal to no panel reactive antibody responses to either major histocompatibility complex I or II antigen. Immunohistochemistry correlated with the panel reactive antibody results by identifying significant amounts of major histocompatibility complex I and II in fresh tissue, reduced antigen staining in cryopreserved control tissues, and minimal amounts in decellularized tissues.

CONCLUSIONS: These studies with an ovine modified panel reactive antibody assay confirmed minimal immune allosensitization to transplanted decellularized tissue patches. Qualifying criteria for putative tissue-engineered scaffolds should include minimal recipient panel reactive antibody response.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. J. Lehr, G. R. Rayat, L. S. Desai, J. Y. Coe, G. S. Korbutt, and D. B. Ross
Inbred or outbred? An evaluation of the functional allogenicity of farm sheep used in cardiac valve studies.
J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1156 - 1161.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
G. Van Nooten, P. Somers, M. Cornelissen, S. Bouchez, F. Gasthuys, E. Cox, L. Sparks, and K. Narine
Acellular porcine and kangaroo aortic valve scaffolds show more intense immune-mediated calcification than cross-linked Toronto SPV(R) valves in the sheep model
Interactive CardioVascular and Thoracic Surgery, October 1, 2006; 5(5): 544 - 549.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. A. Hopkins
Bioprosthetic Valves and Laudable Inflammation?
Circulation, July 25, 2006; 114(4): 261 - 264.
[Full Text] [PDF]

Home page
 CirculationHome page
R. A. Hopkins
Tissue Engineering of Heart Valves: Decellularized Valve Scaffolds
Circulation, May 31, 2005; 111(21): 2712 - 2714.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.